Should I buy or sell Passage Bio stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PASG shares. View PASG analyst ratings or view top-rated stocks .

What is Passage Bio's stock price target for 2024?

3 equities research analysts have issued 1-year price targets for Passage Bio's stock. Their PASG share price targets range from $5.00 to $14.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 640.7% from the stock's current price. View analysts price targets for PASG or view top-rated stocks among Wall Street analysts .

How have PASG shares performed in 2024?

Passage Bio's stock was trading at $1.01 at the beginning of 2024. Since then, PASG stock has increased by 24.8% and is now trading at $1.26. View the best growth stocks for 2024 here .

When is Passage Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PASG earnings forecast .

How were Passage Bio's earnings last quarter?

Passage Bio, Inc. (NASDAQ:PASG) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.03.

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , DocuSign (DOCU) , Intel (INTC) , Alteryx (AYX) , Gossamer Bio (GOSS) , JD.com (JD) , Micron Technology (MU) and Black Diamond Therapeutics (BDTX) .

When did Passage Bio IPO?

Passage Bio (PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager.

How do I buy shares of Passage Bio?

Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:PASG

Passage Bio (PASG) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free PASG Stock Alerts

$1.26

+0.03 (+2.44%)

(As of 08:48 AM ET)

Compare

Today's Range: $1.26
▼
$1.26
50-Day Range: $0.99
▼
$1.73
52-Week Range: $0.58
▼
$1.79

Volume: 1,006 shs
Average Volume: 376,959 shs
Market Capitalization: $77.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.33

Get Passage Bio alerts:

Passage Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 640.7% Upside
$9.33 Price Target
Short Interest: Healthy
3.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$3,015 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.27) to ($0.79) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.20 out of 5 stars

Medical Sector

329th out of 928 stocks

Biological Products, Except Diagnostic Industry

47th out of 156 stocks

3.5

Analyst's Opinion

Consensus Rating
Passage Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Passage Bio has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.57% of the float of Passage Bio has been sold short.
Short Interest Ratio / Days to Cover
Passage Bio has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Passage Bio has recently increased by 9.09%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Passage Bio does not currently pay a dividend.
Dividend Growth
Passage Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PASG.

3.3

News and Social Media Coverage

News Sentiment
Passage Bio has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Passage Bio this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for PASG on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
MarketBeat Follows
5 people have added Passage Bio to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Passage Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,015.00 in company stock.
Percentage Held by Insiders
14.10% of the stock of Passage Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Passage Bio are expected to grow in the coming year, from ($1.27) to ($0.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Passage Bio is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Passage Bio is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Passage Bio has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Passage Bio Stock (NASDAQ:PASG)

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

PASG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PASG Stock News Headlines

March 20, 2024 | finance.yahoo.com

PASG Apr 2024 7.500 call

March 16, 2024 | finance.yahoo.com

PASG Apr 2024 5.000 call

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 6, 2024 | investorplace.com

PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023

March 5, 2024 | finance.yahoo.com

Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program

March 4, 2024 | globenewswire.com

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

March 3, 2024 | msn.com

Passage Bio to Showcase Advancements at Major Health Care Conferences

February 27, 2024 | globenewswire.com

Passage Bio to Participate in Upcoming Investor Conferences

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

February 20, 2024 | investing.com

Passage Bio Inc (PASG)

February 16, 2024 | investing.com

PASG/USD - Passage US Dollar

February 12, 2024 | finance.yahoo.com

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

February 2, 2024 | msn.com

Passage Bio CEO to Address Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 31, 2024 | finance.yahoo.com

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

December 21, 2023 | benzinga.com

Passage Bio Stock (NASDAQ:PASG) Dividends: History, Yield and Dates

December 20, 2023 | msn.com

Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities

December 20, 2023 | markets.businessinsider.com

Passage Bio Announces Initial Clinical Data From Phase 1/2 UpliFT-D Trial On PBFT02

December 20, 2023 | finance.yahoo.com

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

November 22, 2023 | morningstar.com

Passage Bio Inc Ordinary Shares

November 15, 2023 | benzinga.com

Passage Bio Stock (NASDAQ:PASG) Earnings Dates and Earning Calls

November 15, 2023 | markets.businessinsider.com

Passage Bio Earns Buy Rating Based on Robust Financial Position and Promising AAV1-based GT PBFT02 Trial

November 13, 2023 | fr.investing.com

Le BPA de Passage Bio a manqué les attentes de 0,03$, le CA conforme aux prévisions

November 13, 2023 | msn.com

Passage Bio GAAP EPS of -$0.49 misses by $0.03

November 13, 2023 | benzinga.com

Recap: Passage Bio Q3 Earnings

November 13, 2023 | finance.yahoo.com

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

November 10, 2023 | morningstar.com

Passage Bio Inc Ordinary Shares PASG

October 30, 2023 | benzinga.com

Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

See More Headlines

Receive PASG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:PASG
CUSIP: N/A
CIK: 1787297
Web: www.passagebio.com
Phone: 267-866-0311
Fax: N/A
Employees: 58
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.33
High Stock Price Target: $14.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +640.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-102,060,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -73.12%
Return on Assets: -56.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.22
Quick Ratio: 7.22

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.03 per share
Price / Book: 0.62

Miscellaneous

Outstanding Shares: 61,610,000
Free Float: 52,925,000
Market Cap: $77.63 million
Optionable: Optionable
Beta: 1.30

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. William Chou M.D. (Age 50)
President, CEO & Director
Comp: $395.43k
Mr. Edgar B. Cale Esq. (Age 60)
J.D., General Counsel & Company Secretary
Comp: $674.36k
Dr. James M. Wilson M.D. (Age 69)
Ph.D., Co-Founder & Chief Scientific Advisor
Ms. Kathleen Borthwick (Age 47)
Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer
Mr. Stuart M. Henderson
Senior Vice President of Corporate Development & Investor Relations
Gregory Fuest
Vice President of Global Commercial Strategy & Marketing
Dr. Mark Forman M.D. (Age 60)
Ph.D., Chief Medical Officer
Eden Fucci
Senior Vice President of Technical Operations
Dr. Sue Browne Ph.D.
Senior Vice President of Research & Development
Dr. Karl Whitney Ph.D.
Senior Vice President of Global Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PASG Stock Analysis - Frequently Asked Questions

Should I buy or sell Passage Bio stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PASG shares.
View PASG analyst ratings or view top-rated stocks.
What is Passage Bio's stock price target for 2024?: 3 equities research analysts have issued 1-year price targets for Passage Bio's stock. Their PASG share price targets range from $5.00 to $14.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 640.7% from the stock's current price.
View analysts price targets for PASG or view top-rated stocks among Wall Street analysts.
How have PASG shares performed in 2024?: Passage Bio's stock was trading at $1.01 at the beginning of 2024. Since then, PASG stock has increased by 24.8% and is now trading at $1.26.
View the best growth stocks for 2024 here.
When is Passage Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PASG earnings forecast.

How were Passage Bio's earnings last quarter?: Passage Bio, Inc. (NASDAQ:PASG) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.03.
What other stocks do shareholders of Passage Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX).
When did Passage Bio IPO?: Passage Bio (PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager.
How do I buy shares of Passage Bio?: Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PASG) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Passage Bio (PASG) Stock Price, News & Analysis

Passage Bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Passage Bio Stock (NASDAQ:PASG)

PASG Stock Price History

PASG Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PASG Stock Analysis - Frequently Asked Questions

Overall MarketRank^™